The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12625001151426
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/10/2025
Date registered
Help: Date registered
21/10/2025
Date last updated
Help: Date last updated
28/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/10/2025
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
High dose palliative radiotherapy in patients with metastatic malignancy who cannot or will not have standard of care such as chemotherapy or other drug treatment
Scientific title
Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy
Additional trial identifiers [1] 315540 0
Nil known
Universal Trial Number (UTN)
Trial acronym
HD-PRiMe
Related trial records

Health condition
Health condition(s) studied:
metastatic cancer 339146 0
metastatic malignancy 339147 0
oesophageal cancer 339148 0
pancreatic cancer 339149 0
head and neck cancer 339150 0
cutaneous squamous cell carcinoma 339151 0
colorectal cancer 339152 0
bladder cancer 339153 0
triple-negative breast cancer 339154 0
non-small cell lung cancer 339155 0
skin cancer 339156 0
Condition category
Condition code
Cancer 335432 335432 0 0
Bladder
Cancer 335433 335433 0 0
Bowel - Anal
Cancer 335434 335434 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Cancer 335435 335435 0 0
Breast
Cancer 335436 335436 0 0
Cervical (cervix)
Cancer 335437 335437 0 0
Head and neck
Cancer 335438 335438 0 0
Kidney
Cancer 335439 335439 0 0
Lung - Non small cell
Cancer 335440 335440 0 0
Pancreatic
Cancer 335441 335441 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Patients will receive standard doses of high-dose palliative radiotherapy to sites of metastatic disease until all known sites of disease have been treated.

Each treatment course will consist of 5 treatments delivered 2-3x per week over the course of 2 weeks. Up to six sites of disease will be treated concurrently. If required, further sites will be treated after a four week break with this process repeated until all known disease has been treated. Radiotherapy dose and fractionation will be between 20Gy-30Gy in 5 fractions depending on location and size of tumour. There is no maximum number of treatment courses set that can be delivered to patients. There is a minimum of 1 treatment course. Patients will be asked to undergo one or multiple different types of CT scans and/or a PET scan to assess the impact of radiotherapy on the metastases. The treating clinician will then determine if further treatment is required.

Patients will have radiotherapy planning performed approximately 2 weeks prior to radiotherapy treatment. Treatment will be delivered in line with standard practice at Sunshine Coast University Hospital and will be overseen by a Senior Radiation Oncologist. Adherence will be monitored by review of electronic medical records.
Intervention code [1] 332166 0
Treatment: Devices
Intervention code [2] 332167 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 343005 0
Recruitment rate and proportion of patients receiving high dose palliative radiotherapy in patients with newly diagnosed de novo metastatic malignancy or for patients with metastatic malignancy with disease progression on systemic therapy.
Timepoint [1] 343005 0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Secondary outcome [1] 453107 0
Progressional-free survival (PFS)
Timepoint [1] 453107 0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Secondary outcome [2] 453108 0
New metastasis-free survival (NMFS)
Timepoint [2] 453108 0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Secondary outcome [3] 453109 0
Overall survival (OS)
Timepoint [3] 453109 0
First analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Secondary outcome [4] 453110 0
Clinician reported acute radiotherapy-related toxicity
Timepoint [4] 453110 0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)
Secondary outcome [5] 453111 0
Patient reported quality of life (QoL)
Timepoint [5] 453111 0
Interim analysis at 12 months from study commencement Second interim analysis at 24 months from study commencement Final analysis at 36 months from study commencement or 24 months after last participant recruited (whichever is later)

Eligibility
Key inclusion criteria
Aged 18 years or more.

Able to give informed consent.

Metastatic cancer (TxNxM>0 or International Federation of Gynecology and Obstetrics (FIGO) IV) based on staging CT-CAP +/- CT-B +/- CT-N or whole-body PET-CT +/- CT-B.

Burden of disease able to be encompassed within standard organ at risk (OAR) constraints.

Eastern Cooperative Oncology Group (ECOG) status 0-2.

Patient deemed unsuitable for systemic therapy by treating Medical Oncologist OR patient declined systemic therapy offered by Medical Oncologist.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients currently receiving systemic therapy (cytotoxic chemotherapy, immunotherapy, biologic, hormone, or molecularly targeted therapy).

Patients with metastatic malignancy with disease progression whilst receiving systemic therapy that do not have a further line of systemic therapy available to them.

Life expectancy <3 months.

Breast (except for triple negative disease), prostate, haematological or primary central nervous system (CNS) malignancies.

Intracranial metastases not suitable for localised treatment (i.e., resection or stereotactic radiotherapy).

Previous radiotherapy precluding treatment of current metastatic sites.

Pregnancy.

Intercurrent illness that will interfere with radiotherapy delivery.

Treatment toxicity expected to reduce QoL significantly e.g., treatment to bilateral parotids.

Prior diagnosis of connective tissue disorder.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 28620 0
Sunshine Coast University Hospital - Birtinya
Recruitment postcode(s) [1] 44849 0
4575 - Birtinya

Funding & Sponsors
Funding source category [1] 320139 0
Hospital
Name [1] 320139 0
Sunshine Coast University Hospital
Country [1] 320139 0
Australia
Primary sponsor type
Hospital
Name
Sunshine Coast University Hospital
Address
Country
Australia
Secondary sponsor category [1] 322701 0
None
Name [1] 322701 0
Address [1] 322701 0
Country [1] 322701 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318685 0
Metro North Health Human Research Ethics Committee
Ethics committee address [1] 318685 0
Ethics committee country [1] 318685 0
Australia
Date submitted for ethics approval [1] 318685 0
26/06/2021
Approval date [1] 318685 0
24/08/2021
Ethics approval number [1] 318685 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144934 0
Dr Myo Min
Address 144934 0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Country 144934 0
Australia
Phone 144934 0
+61 07 5202 8257
Fax 144934 0
Email 144934 0
Contact person for public queries
Name 144935 0
Dr Mark Windsor
Address 144935 0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Country 144935 0
Australia
Phone 144935 0
+61 07 5202 0651
Fax 144935 0
Email 144935 0
Contact person for scientific queries
Name 144936 0
Dr Myo Min
Address 144936 0
Sunshine Coast University Hospital, 6 Doherty Street Birtinya, QLD, 4575
Country 144936 0
Australia
Phone 144936 0
+61 07 5202 8257
Fax 144936 0
Email 144936 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers

• Participants involved in this research will be able to request access to their de-identified data. All data will be de-identified prior to sharing.

Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Email of contacts listed on this trial registration as per below:
[email protected]
[email protected]


Are there extra considerations when requesting access to individual participant data?
Yes: Departmental policies may be an extra consideration when requesting access to individual participant data.




What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Informed consent form    Participant information and consent form can be re... [More Details]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.